It is “not yet” necessary to adapt the Pfizer vaccine to the variants, said the boss of BioNTech, the laboratory which developed the messenger RNA vaccine jointly with the American firm.
The anti-Covid vaccine from Pfizer / BioNTech laboratories “does not yet” need to be adapted to the new variants of the coronavirus in circulation, assured at a press conference Monday the boss of BioNTech, recommending instead a “third dose ”.
The best approach: “a booster dose”
“It is possible that in the next 6 to 12 months, a variant will emerge that requires adaptation of the vaccine, but this is not yet the case,” said Ugur Sahin.
“The best approach to deal with this situation is to continue with a booster dose,” he added.